Antineoplastic drugs, also known as cytotoxic or hazardous drugs, are necessary tools in cancer treatment. However, many antineoplastic drugs can also cause cancer later in life. While this risk may be acceptable to a patient currently suffering from cancer, incidental exposure among workers is an emerging concern. According to CAREX (CARcinogen EXposure) Canada, approximately 75,000 Canadians are occupationally exposed to antineoplastic drugs, primarily in pharmacy and healthcare environments. Upon communicating these research findings to practice and policy specialists, a large evidence gap around controlling and reducing occupational exposures to antineoplastic drugs was identified. This study’s objective is to identify the policy levers for controlling exposure to antineoplastic drugs and best practices for safe handling of antineoplastic drugs. We will:
- conduct a scan to develop an inventory of policy levers and best practices,
- develop a logic model to analyze the effect of each policy,
- engage key informants to verify the logic model and appraise individual policies and practices, and
- consult with end users and experts to contextualize the results.
By summarizing the findings in a compendium, we will be able to effectively share the current state of knowledge, and to provide practical and evidence‐based guidance to stakeholders on how to reduce antineoplastic drug exposure in the workplace.
Co-Principal Investigators: Dr. Cheryl Peters, Dr. Darren Brenner
Funder:: Alberta Ministry of Labour and Immigration